Other Mutations: NRAS

NCT03919292: Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

NCT03919292
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS, NRAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only patients with RAS-mutated solid tumors are eligible for phase 2
Exclusions: Patients with current or prior known meningeal metastases; Patients with symptomatic untreated brain metastases – see trial for details; Patients with previous therapy with neratinib
https://ClinicalTrials.gov/show/NCT03919292

NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, EGFR, HER2, MET, ALK, ROS, BRAF, PI3K, FGFR, mTOR, TSC, PTEN, NF1/2, GNA, SMO, PTCH, KIT, Akt, NRAS, CDK, Rb+, MLH, NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Any patient with a solid tumor is eligible; The trial matches patients to a specific experimental arm based on the mutations or molecular information of the tumor- see trial for full list of eligible mutations
Exclusions: Patients with brain metastases must have completed treatment, surgery or radiation therapy
https://clinicaltrials.gov/show/NCT02465060

Up ↑